Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Reviva Pharmaceuticals Holdings Inc has a consensus price target of $14.75 based on the ratings of 5 analysts. The high is $17 issued by Benchmark on August 26, 2024. The low is $12 issued by Roth MKM on October 30, 2023. The 3 most-recent analyst ratings were released by Benchmark, HC Wainwright & Co., and HC Wainwright & Co. on August 26, 2024, July 11, 2024, and June 20, 2024, respectively. With an average price target of $15 between Benchmark, HC Wainwright & Co., and HC Wainwright & Co., there's an implied 979.14% upside for Reviva Pharmaceuticals Holdings Inc from these most-recent analyst ratings.
1calculated from analyst ratings
The latest price target for Reviva Pharmaceuticals (NASDAQ:RVPH) was reported by Benchmark on August 26, 2024. The analyst firm set a price target for $17.00 expecting RVPH to rise to within 12 months (a possible 1123.02% upside). 14 analyst firms have reported ratings in the last year.
The latest analyst rating for Reviva Pharmaceuticals (NASDAQ:RVPH) was provided by Benchmark, and Reviva Pharmaceuticals reiterated their speculative buy rating.
There is no last upgrade for Reviva Pharmaceuticals
The last downgrade for Reviva Pharmaceuticals Holdings Inc happened on August 16, 2024 when Maxim Group changed their price target from N/A to N/A for Reviva Pharmaceuticals Holdings Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Reviva Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Reviva Pharmaceuticals was filed on August 26, 2024 so you should expect the next rating to be made available sometime around August 26, 2025.
While ratings are subjective and will change, the latest Reviva Pharmaceuticals (RVPH) rating was a reiterated with a price target of $17.00 to $17.00. The current price Reviva Pharmaceuticals (RVPH) is trading at is $1.39, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.